RecruitingNCT03995121

SV2 PET Imaging With [11C]APP311

Synaptic Density in Psychiatric Disorders Using SV2A Receptor PET Imaging With [11C]APP311

Sponsor

Yale University

Enrollment

250 participants

Start Date

Dec 1, 2017

Study Type

OBSERVATIONAL

Conditions

Healthy Cannabis Use Disorder Schizophrenia and Other Psychotic Disorders

Summary

The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new type of brain imaging using a special radioactive tracer called [11C]APP311, which is designed to highlight a protein in the brain called SV2. The goal is to see if this PET scan can safely and accurately show brain activity in healthy volunteers and potentially help detect neurological conditions in the future. **You may be eligible if...** - You are between 18 and 65 years old - You are willing and able to give written informed consent - You are male or female **You may NOT be eligible if...** - You have metal implants in your body or are claustrophobic (preventing you from having an MRI scan) - You completed less than 12 years of formal education Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[11C]APP311

It has been shown that radiotracer \[11C\]APP311 (aka \[11C\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.